A new test could be more effective at detecting dangerous prostate cancer than current screening methods, a study suggests.
In this randomized screening trial, the multivariable Stockholm3 test provided greater clinical net benefit and substantially ...
The FDA’s approval of the first point-of-care total PSA test for prostate cancer has the potential to improve patient care by streamlining PSA testing. However, a Clinical Laboratory Improvement ...